Evidence based medicine: Recommendations for pharmacological treatment of osteoarthritis patients;Medicina temeljena na dokazima: Preporuke za farmakološko liječenje bolesnika s osteoartritisom

Medicus

Volumn 13, Issue 1, 2004, Pages 121-126

  Kopjar, Branko ^a   Ćurković, Božidar ^b   Grazio, Simeon ^c   Vlak, Tonko ^d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b KBC Zagreb   (Croatia)

^c SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^d UNIVERSITY HOSPITAL SPLIT   (Croatia)

Author keywords

Non steroidal anti inflammatory drugs; Osteoarthritis

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ANALGESIA; CLINICAL TRIAL; COCHRANE LIBRARY; DRUG COST; DRUG EFFICACY; DRUG MARKETING; EMBASE; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; HUMAN; LONG TERM CARE; MEDICAL DECISION MAKING; MEDLINE; META ANALYSIS; OSTEOARTHRITIS; REVIEW; SIDE EFFECT; STATISTICS; SYSTEMATIC REVIEW;

EID: 14544276982     PISSN: 1330013X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. FORMAN MD, MALAMET R, KAPLAN D. A survey of osteoarthritis of the knee in the elderly. J Rheumatol 1983; 10: 282-7.
2. Centers for Disease Control and Prevention. Prevalence of disabilities and associated health conditions - United States, 1991-1992. JAMA 1994; 272: 735-6.
3. Van BAAR ME, ASSENDELFT WJ, DEKKER J, OOSTENDORP RA, BIJLSMA JW. Effectiveness of exercise therapy in patients with osteoarthritis of the hip or knee: a systematic review of randomized clinical trials. Arthritis Rheum 1999; 42: 1361-9.
4. OOSTERVELD FG, RASKER JJ. Effects of local heat and cold treatment on surface and articulare temperature of arthritic knees. Arthritis Rheum 1994; 37: 1578-82.
5. LEWIS B, LEWIS D, CUMMING G. The comparative analgesic efficacy of transcutaneous electrical nerve stimulation and a non-steroidal anti-inflammatory drug for painfull osteoarthritis. Br J Rheumatol 1994; 33: 455-60.
6. SUPERIO-CABUSLAY E, WARD MM, LORIG KR. Patient education interventions in osteoarthritis and rheumatoid arthritis: a meta-analytic comparison with non-steroidal anti-inflammatory drug treatment. Arthritis Care Res 1996; 9: 292-301.
7. CREAMER P. Intra-articular corticosteroid treatment in osteoarthritis. Curr Opin Rheumatol 1999; 11: 417-21.
8. KNUTSON K. Arthroplasty and its complications. U: Brandt KD, Doherty M, Lohmander LS, ur. Osteoarthritis. Oxford UK: Oxford University Press; 1998, str. 388 -402.
9. WARNER TD, GIULIANO F, VOJNOVIC I, BUKASA A, MITCHELL JA, VANE JR. Non-steroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999;96:7563-8.
10. RYCROFT-MALONE J, KITSON A, HARVEY G, McCORMACK B, SEERS K, TITCHEN A, ESTABROOKS C. Ingredients for change: revisiting a conceptual framework. Qual Saf Health Care 2002;11:174-80.
11. BROOKS PM, DAY RO. Nonsteroidal anti-inflammatory drugs-differences and similarities. N Eng J Med 1991;324:1716-25.
12. TOWHEED TE, SHEA B, WELLS G, HOCHBERG M. Analgesia and non-aspiring, non-steroidal anti-inflammatory drugs for osteoarthritis of the hip. The Cochrane Library 2000; Issue 3.
13. TOWHEED TE, HOCHBERG MC. A systematic review of randomized controlled trials of pharmacological therapy in osteoarthritis of the knee, with an emphasis on trial methodology. Semin Arthritis Rheum 1997; 26: 755-70.
14. TOWHEED TE, HOCHBERG MC. A systematic review of randomized controlled trials of pharmacological therapy in osteoarthritis of the hip. J Rheumatol 1997; 24: 349-57.
15. WATSON MC, BROOKES ST, KIRWAN JR, FAULKNER A. Osteorathritis: the comparative efficacy of non-aspiring non-steroidal anti-inflammatory drugs for the management of osteoarthritis of the knee. The Cochrane Library 2002; Issue 1.
16. GOTZSCHE P. Meta-analysis of NSAIDs: contribution of drugs, doses, trial designs, and meta-analytic techniques. Scand J Rheumatol 1993; 22(6): 255-60.
17. SILVERSTEIN FE, FAICH G, GOLDSTEIN JL i sur. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-55.
18. CANNON GW, CALDWELL JR, HOLT P i sur. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of one-year, randomized clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group. Arthritis Rheum 2000; 43: 978-87.
19. SAAG K, VAN DER HEIJDE D, FISHER C, i sur. Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy comparable, with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group. Arch Fam Med 2000; 9: 1124-34.
20. GARCIA RODRIGUEZ LA. Nonsteroidal anti-inflammatory drugs, ulcers and risk: a collaborative meta-analysis. Semin Arthritis Rheum 1997; 26(6 Suppl 1): 16-20.
21. HENRY D, LIM LL, GARCIA RODRIGUEZ LA i sur. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312: 1563-6.
22. GARCIA RODRIGUEZ LA. Variability in risk of gastrointestinal complications with different nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104(3A): 30S-34S.
23. BOLLINI P, GARCIA RODRIGUEZ LA, PEREZ GUTTHANN S, WALKER AM. The impact of research quality and study design on epidemiologic estimates of the effect of nonsteroidal anti-inflammatory drugs on upper gastrointestinal tract disease. Arch Intern Med 1992; 152: 1289-95.
24. LANZA LL, WALKER AM, BORTNICHAK EA, DREYER NA. Peptic ulcer and gastrointestinal hemorrhage associated with nonsteroidal anti-inflammatory drug use in patients younger than 65 years. A large health maintenance organization cohort study. Arch Intern Med 1995; 155: 1371-7.
25. CHALMERS TC, BERRIER J, HEWITT P i sur. Meta-analysis of randomized controlled trials as a method of estimating rare complications of non-steroidal anti-inflammatory drug therapy. Aliment Pharmacol Ther 1988 (2 Suppl 1): 9-26.
26. KURATA JH, NOGAWA AN. Meta-analysis of risk factors for peptic ulcer. Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and smoking. J Clin Gastroenterol 1997; 24: 2-17.
27. ROSTOM A, WELLS G, TUGWELL P, WELCH V, DUBE C, MCGOWAN J. The prevention of chronic NSAID induced upper gastrointestinal toxicity: a Cochrane collaboration metaanalysis of randomized controlled trials. J Rheumatol 2000; 27: 2203-14.
28. LEANDRO G, PILOTTO A, FRANCESCHI M, BERTIN T, LICHINO E, DI MARIO F. Prevention of acute NSAID-related gastroduodenal damage: a meta-analysis of controlled clinical trials. Dig Dis Sci 2001;46:1924-36.
29. HAWKEY CJ, LANAS AI, Sardinia NSAID meeting. Doubt and certainty about nonsteroidal anti-inflammatory drugs in the year 2000: a multidisciplinary expert statement. Am J Med 2001;110: 79S-100S.
30. BOMBARDIER C, LAINE L, REICIN A i sur. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8.
31. JUNI P, RUTJES AW, DIEPPE PA. Are selective COX 2 inhibitors superior to traditional non-steroidal anti-inflammatory drugs? BMJ 2002;324:1287-8.
32. MANOUKIAN AV, CARSON JL. Nonsteroidal anti-inflammatory drug-induced hepatic disorders. Incidence and prevention. Drug Saf 1996;15:64-71.
33. MUKHERJEE D, NISSEN SE, TOPOL EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9.
34. CATELLA-LAWSON F, CROFFORD LJ. Cyclooxygenase inhibition and thrombogenicity. Am J Med 2001;110 (Suppl 3A):28S-32S.
35. KONSTAM MA, WEIR MR, REICIN A i sur. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001;104:2280-8.
36. Food and Drug Administration. Arthritis Advisory Committee open panel meeting 2/8/2001: review of VIGOR, cardiovascular safety review of rofekoxib. Dostupno na URL adresi: http://www.fda.gov/ohrms/dockets/ac/01/briefing/ 36772b_03med.pdf. Datum pristupa informaciji, 5. svibnja 2004.
37. STRAND V, HOCHBERG MC. The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors. Arthritis Rheum 2002;47:349-55.
38. GARCIA RODRIGUEZ LA. The effect of NSAIDs on the risk of coronary heart disease: fusion of clinical pharmacology and pharmacoepidemiologic data. Clin Exp Rheumatol 2001;19(6 Suppl 25):S41-4.
39. LAINE L, BOMBARDIER C, HAWKEY C, SHAPIRO D, REICIN A. Influence of H. pylori and other potential risk factors on clinical GI events in a double-blind outcome study of rofecoxib versus naproxen. Gastroenterology 2000; 118: A862.
40. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000; 43: 1905-15.
41. PINCUS T, KOCH GG, SOKKA T i sur. A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum 2001; 44: 1587-98.